Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 5Thromboembolism 2Hemorrhage 2Venous Thrombosis 1Thrombosis 1Stomach Neoplasms 1Pulmonary Embolism 1Liver Neoplasms 1Gastrointestinal Neoplasms 1Fibrosis 1Colorectal Neoplasms 1Carcinoma, Pancreatic Ductal 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 15130-nm albumin-bound paclitaxel 10Albumin-Bound Paclitaxel 7Oxaliplatin 5Paclitaxel 4Leucovorin 4Fluorouracil 4Carboplatin 4Cisplatin 3Cetuximab 3Bevacizumab 3pembrolizumab 2napabucasin 2Pemetrexed 2PEGPH20 2MK-4721 2Irinotecan 2tremelimumab 1selinexor 1relacorilant 1ponatinib 1neratinib 1irinotecan sucrosofate 1folfirinox 1ensituximab 1durvalumab 1contrast agent BR1 1cobimetinib 1ceritinib 1cc-486 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Pancreatic Ductal × Enoxaparin × Gastrointestinal × Clear all
NCT01839487 2020-07-20

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Halozyme Therapeutics

Phase 2 Completed
279 enrolled 19 charts
Gastrointestinal

Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡